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In the past decade, several kinase inhibitors have been approved based on their clinical beneﬁt for cancer
patients. Unfortunately, in many cases, patients develop resistance to these agents via secondary muta-
tions and alternative mechanisms. This review will focus on the cases of acquired resistance to EGFR and
ALK inhibitors for non-small cell lung cancer patients and BRAF inhibitors for melanoma patients. I will
overview the main causes of acquired resistance, and explore the chemical scaffolds as well as combina-
tion of drugs, used to tackle these major causes of resistance.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license. EGFR inhibitors for the treatment of NSCLC
Lung cancer accounts for approximately 30% of all deaths from
cancer worldwide. In North America, lung cancer is the leading
cause of cancer-related deaths.1 The disease comprises two broad
classes: small-cell lung cancer (SCLC, ca. 20% incidence) and non-
small cell lung cancer (NSCLC, ca. 80% incidence). NSCLC is further
divided into three main histological subtypes: adenocarcinoma,
squamous cell lung carcinoma and large cell lung carcinoma.2
The past two decades of intense academic and pharmaceutical re-
search has led to the validation of several biological targets and a
deeper understanding of the activating mutations underlying the
disease. Amongst the validated targets, the epidermal growth fac-
tor receptor (EGFR) has emerged as a target of choice for the phar-
maceutical industry. EGFR (ERBB1 or HER1) belongs to the ERBB
family which also includes ERBB2 (HER2 or neu), ERBB3 (HER3)
and ERBB4 (HER4). Upon activation by extra-cellular growth fac-
tors (such as EGF and TGF-a), these receptor tyrosine kinases
(RTKs) undergo homo- and hetero-dimerization leading to the
phosphorylation of their respective tyrosine kinase domains. Once
phosphorylated, these receptors mediate downstream cellular sig-
naling.2 The two main signaling pathways activated by EGFR are
the RAS/RAF/MEK/ERK pathway and the PI3K/AKT pathway, which
lead to evasion of apoptosis (cell survival) and cell proliferation.3,4
EGFR is often ampliﬁed, mutated, or overexpressed in the tumors
of NSCLC patients, thus it is not surprising that substantial efforts
were made towards the inhibition of its kinase activity. To this
end, geﬁtinib (Iressa™, AstraZeneca) gained fast-track approval
from the FDA in 2003, closely followed by erlotinib (Tarceva™,Y-NC-ND license. Genentech) which received FDA approval in 2004.5 Both of these
small molecules (Fig. 1) selectively target the tyrosine kinase activ-
ity of EGFR and are ATP-competitive, reversible inhibitors.
In 2004, it was uncovered that the response rates to EFGR tyro-
sine kinase inhibitor-based therapies strongly correlate with the
presence of activating somatic mutations in the EGFR kinase do-
main.6–10 Those mutations were discovered after sequencing the
EGFR gene in tumor samples of responders. More speciﬁcally, in-
frame deletions of amino acids 747–750 in exon 19 and single
point mutations in exon 21, such as the substitution of leucine
858 for an arginine (L858R), account for approximately 46% and
40% of the mutations respectively.8 In North America and Europe,
approximately 10% of the NSCLC patient population harbors these
activating ‘‘gain-of-function’’ mutations. This is in signiﬁcant con-
trast to the Asian patient population, where these activating muta-
tions are present in 25–50% of the NSCLC cases, with the highest
prevalence in Asian females, non-smokers and in patients with
adenocarcinoma histology.9 Consequently, early clinical trials that
included all patients showed only modest response rates to geﬁti-
nib and erlotinib.10 Subsequently, clinical trials such as IPASS
(Iressa™ Pan-Asia Study)11 demonstrated clearly that NSCLC
patients with EGFRmutations have higher objective response rates
(ORR) (71% vs 1% in EGFR mutation-negative), longer progression-
free survival (PFS) (9.6 mo vs 1.6 mo in EGFR mutation-negative)
and an improved quality of life. Moreover, EGFR mutation-positive
patients had better response rates and progression-free survival
with EGFR inhibition than standard chemotherapy (carboplatin-
paclitaxel).11
Unfortunately, many of those patients who originally had re-
sponded eventually become insensitive to geﬁtinib or erlotinib
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Figure 1. Selected 1st, 2nd and 3rd generation EGFR inhibitors for NSCLC.
S. Giroux / Bioorg. Med. Chem. Lett. 23 (2013) 394–401 395resistance’’ usually occurs within a year from the start of the treat-
ment. A major cause that accounts for approximately 50% of the ac-
quired resistance cases is the development of a secondary
mutation in exon 20 of the EGFR gene. This mutation is a substitu-
tion of a hydrophilic threonine residue for a bulkier and hydropho-
bic methionine in codon 790 (T790M). The threonine residue 790 is
known as the ‘‘gatekeeper residue’’ and is located in the ATP-bind-
ing site, adjacent to the catalytic cleft of the kinase domain.12 It
was initially proposed that the T790M mutation might prevent
the proper binding of tyrosine kinase inhibitors via steric hin-
drance, similar to the corresponding gatekeeper mutations in
BCR-ABL (T315I)13 and KIT (T670I)14 that confer resistance to imati-
nib (Gleevec™) in chronic myelogenous leukemia (CML) and in pa-
tients with gastrointestinal stromal tumors (GIST). Interestingly, it
was discovered that the T790M mutation does not confer resis-
tance to geﬁtinib and erlotinib by preventing their binding as orig-
inally thought. Instead, the T790M mutation induces resistance by
increasing the binding afﬁnity of ATP by one order of magnitude,
which is near the afﬁnity for wild-type EGFR, thus enabling ATP
to compete effectively with the kinase inhibitors.15
Second generation inhibitors, designed to address resistance,
are currently under investigation in clinical trials.16 The two mostFigure 2. (A) Erlotinib (magenta) bound to the EGFR tyrosine kinase, the gatekeeper resi
2nd and 3rd generations irreversible EGFR inhibitors is highlighted in green (PDB code:
(PDB code: 3IKA).advanced compounds are dacomitinib (EGFR/HER2/HER4: IC50 = 6
nM/46 nM/73 nM, Pﬁzer) and afatinib (EGFR/HER2: IC50 = 0.5 nM/
14 nM, Boehringer-Ingelheim) which are currently in phase III.16
Both of these agents are structurally very similar to geﬁnitib and
erlotinib with the exception that they harbor Michael acceptors
in the side chain of the quinazoline core (highlighted in red,
Fig. 1). This leads to dacomitinib and afatinib to be irreversible
inhibitors of EGFR.17 More speciﬁcally, they covalently bind to
Cys-797 of EGFR via the sulfur atom (see Fig. 2). Due to their cova-
lent binding mode, irreversible inhibitors have activity towards
EGFRT790M, EGFRT790M/L858R as well as wild-type EGFR. Conse-
quently, dose limitation due to the concomitant inhibition of
wild-type EGFR is a potential concern and, in clinical settings, this
accompanying inhibition translates into skin rash and diarrhea.18
The results of several phase III clinical trials for dacomitinib and
afatinib are awaited in 2013.
More recently, ‘third generation’ inhibitors which have an
anilinopyrimidine core (such has WZ-4002, Figs. 1 and 2) have
been identiﬁed via high throughput screening (HTS) of a library
of irreversible kinase inhibitors.19 Notably, anilinopyrimidine-
based irreversible inhibitors are 30- to 100-fold more potent
against EGFRT790M than other ﬁrst and second generation inhibitorsdue (T790) is highlighted in green; cysteine-797 which forms a covalent bond with
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Figure 3. Representative chemical structures of c-MET and HSP90 inhibitors given in combination with EGFR inhibitors in NSCLC patients.
396 S. Giroux / Bioorg. Med. Chem. Lett. 23 (2013) 394–401and are up to 100-fold less potent against wild-type EGFR. Another
third generation, mutant-selective inhibitor (CO-1686, undisclosed
structure, Clovis Oncology) entered clinical trials in 2012.20 Mu-
tant-selective inhibitors, such as WZ-4002 and CO-1686, could
potentially offer larger therapeutic windows and better toxicity
proﬁles. It remains to be seen how these third generation inhibi-
tors will behave in the clinic.
Another mechanism by which patients develop acquired resis-
tance to EGFR inhibition occurs via the ampliﬁcation of the MET
oncogene.21,22 MET ampliﬁcation occurs in approximately 5–20%
of the NSCLC patients.23 In sensitive cells, the phosphorylation of
ERBB3 by EGFR is inhibited by tyrosine kinase inhibitors. However,
whenMET is ampliﬁed, the proto-oncogene MET compensates, and
phosphorylates ERBB3. Once ERBB3 is phosphorylated, it binds to
the regulatory subunit of PI3K which results in the activation of
p110a (PI3Ka) and its downstream target, AKT (Fig. 7). Thus, upon
MET ampliﬁcation, the activation of the PI3K/AKT pathway leads
to cell survival, even under sustained inhibition of EGFR. The con-
comitant inhibition of MET and EGFR using the monoclonal anti-
boby MetMab and erlotinib proved to be efﬁcacious in a phase II
trial24 and early clinical trials of small-molecule inhibitors of MET
given with EGFR inhibitors are now currently underway (Fig. 3).
These combinations may show improved overall survival (OS) and
progression-free survival (PFS) in certain patients, depending on
their genotypes.25 The combination of crizotinib (dual c-MET/ALK
inhibitor, Fig. 3) and dacomitinib, although in early phase, is partic-
ularly interesting since one of its components, dacomitinib, was
designed to address the acquired resistance by the T790M second-
ary mutation in EGFR. This combination could potentially be effec-
tive in patients with acquired resistance via T790M and/or MET
ampliﬁcation.26
Another potential strategy to overcome acquired resistance is
the use of combination therapies including heat shock protein 90
(HSP90) inhibitors. It has been shown that several EGFR mutants,
such as EGFRL858R/T790M, are client proteins of molecular chaperone
HSP90.27 Additionally, MET is also a client protein of HSP90.28 Two
structurally diverse classes of HSP90 inhibitors have been looked at
in clinical settings: the ansamycin-like derivatives such as IPI-50429
and bi-phenolic derivatives such as AUY92230 and STA9090.31 A
combination of AUY922 and erlotinib is currently in clinical trials
in patients with acquired resistance (Fig. 3).ALK inhibitors for the treatment of NSCLC
In 2007, two research groups independently reported the
discovery of an oncogenic fusion gene (EML4–ALK) that combines
portions of the echinoderm microtubule-associated protein-like 4
(EML4) gene and the anaplastic lymphoma kinase (ALK) gene.32,33
This fusion gene encodes for the cytoplasmic fusion protein
EML4-ALK which, upon dimerization, results in constitutive activa-
tion of the kinase domain of ALK. The downstream pathways acti-
vated by ALK include PI3K/AKT, MEK/ERK and the JAK/STAT
pathways which lead to cell proliferation and cell survival.34 It is
estimated that approximately 5% of all NSCLC cases have EML4–
ALK fusions. Although this appears to be a relatively small percent-
age, because of the high prevalence of lung cancer cases, it would
represent about 70,000 patients worldwide and close to 10,000
in the USA alone.35,36 Similar to the NSCLC patients harboring acti-
vating EGFR mutations, ALK-positive patients are generally non-
smokers with adenocarcinoma histology.37
Strikingly, only 4 years following the discovery of the EML4-ALK
fusion gene, and the subsequent in vitro and in vivo pharmacolog-
ical target validation conﬁrming the oncogenic activity of its en-
coded protein,38,39 EML4–ALK-positive patients were already
taking advantage of ALK inhibitors. For instance, in phase I/II clin-
ical trials, 250 mg twice-daily oral administration of crizotinib, a
dual c-MET/ALK inhibitor, to patients with advanced ALK-positive
NSCLC led to an overall response rate (ORR) of 57% and the pro-
gression-free survival (PFS) at 6 months was estimated to be
72%.40 Notably, all patient tumors tested were negative for MET
ampliﬁcation, suggesting that clinical responses seen with crizoti-
nib is through ALK inhibition. In August 2011, following these po-
sitive results, the FDA approved crizotinib (Xalkori™, Pﬁzer) for
patients with advanced ALK-positive NSCLC as diagnosed using
ﬂuorescence in situ hybridization (FISH)42 with the FDA-approved
Vysis FISH probe kit (Abbott).43 Phase III clinical trials are currently
underway to evaluate the efﬁcacy of crizotinib versus pemetrexed/
docetaxel or versus pemetrexed/platinum-based chemotherapies
in ALK-positive patients (Fig. 4).
The ﬁrst two secondary ALK mutations that conferred resistance
to crizotinib were reported within the same issue of the New Eng-
land Journal of Medicine describing the positive clinical results
mentioned above.44 The molecular analysis of a patient’s tumor,










Figure 5. Crizotinib (magenta) bound to the ALK kinase domain with locations of
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Active Against:
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Figure 4. Representative chemical structures of ALK inhibitors in preclinical and clinical studies.49–56
S. Giroux / Bioorg. Med. Chem. Lett. 23 (2013) 394–401 397who relapsed only 5 months after the beginning of its treatment,
revealed two distinct mutations. Speciﬁcally, a leucine to
methionine mutation at position 1196 (L1196M) and a cysteine
to tyrosine mutation at position 1156 (C1156Y) were found. The
L1196M mutation corresponds to the ‘gatekeeper’ mutation (anal-
ogous to the T790M mutation in EGFR), whereas the C1156Y
mutation is located in the a-C-helix near the upper edge of the
ATP-binding site (Fig. 5).44 The two mutations were shown to inde-
pendently induce crizotinib resistance in Ba/F3 cells engineered to
express the L1196M and C1156Y mutations. By mid-2012,
additional patient studies led to the discovery of several other sec-
ondary mutations.45,46 That is, three other mutations in the a-C-
helix were discovered: a threonine insertion at amino acid 1151
(1151Tins), a leucine to arginine (L1152R) and phenylalanine to
leucine (F1174L). Two other mutations have been discovered at
the solvent interface: a glycine to arginine (G1202R) and a serine
to tyrosine (S1206Y). And ﬁnally, a glycine to alanine mutation
(G1269A) was found in the ATP binding pocket (Fig. 5). Unlike ac-
quired resistance to EGFR inhibitors where the T790M gatekeeper
mutation accounts for approximately all secondary mutations
resistance-driven cases,12,47 the resistance to ALK inhibitors ap-
pears, for now, much more complex since a greater variety of
mutations with similar degrees of frequency is found in patients.
This is reminiscent of BCR-ABL, where almost 20 different second-
ary mutations within the kinase domain have been found.47
To date, several different classes of ALK inhibitors with distinct
chemical scaffolds have been reported,48 and ALK inhibitors that
retain potency against several of these mutations are already under
investigation in the clinic. Some of them, with publicly disclosed
structures, are shown in Figure 4. Currently, CH-542480249 (ChugaiPharmaceuticals), X-39650 (Xcovery), AP-2611351 (Ariad Pharma-
ceuticals) ASP-302652 (Astellas Pharmaceuticals) and LDK-37853
(Novartis) are all under investigation in early clinical trials (for
























Figure 6. Chemical structures of HSP90 inhibitors IPI-504 and STA-9090.
398 S. Giroux / Bioorg. Med. Chem. Lett. 23 (2013) 394–401LDK-378 (up to 500 mg/day) have been seen in crizotinib-naïve
patients, as well as patients who have previously relapsed on
crizotinib.53
Another approach under investigation to tackle ALK inhibitor
resistance is the use of HSP90 inhibitors. As with EGFR and MET,
EML4-ALK is also a client protein of HSP90, thereby stabilizing it.
Moreover, crizotinib-resistant cell line models expressing the
gatekeeper mutation L1196M retain sensitivity to HSP90 inhibi-
tion.51 In clinical settings, the ansamycin derivative IPI-504 (Retas-
pimycin, Inﬁnity Pharmaceuticals) has demonstrated efﬁcacy in
ALK-positive, crizotinib-naïve patients.29 STA-909031 (Ganetespib,
Synta Pharmaceuticals) is presently under investigation in crizoti-
nib-naïve patients (Fig. 6).
The recent studies revealing additional mutations from relaps-
ing patient tumors have also shed light onto other mechanisms
of acquired resistance. At least four other resistance mechanisms
exist amongst the patients examined to date: ampliﬁcation of














Figure 7. Selected small-molecule inhibitors tackling resistance mechanisms in (A)K-RAS mutations.34,45,46 This suggest that the combination of more
than one tyrosine kinase inhibitor (TKI) could potentially be
effective. Of note, two clinical trials involving combinations of
ALK and EGFR inhibitors are underway (crizotinib/dacomitinib:
NCT01121575 and crizotinib/erlotinib: NCT00965731). It is impor-
tant to mention that these clinical trials were designed to investi-
gate MET ampliﬁcation-mediated resistance to EGFR inhibition, as
crizotinib is also a potent inhibitor of c-MET.41 Therefore, these tri-
als are not conducted on pre-selected ALK-positive patients. Lastly,
AP-26113 (Figs. 4 and 7) a dual ALK/EGFR inhibitor is under inves-
tigation in pre-selected ALK-positive patients.
BRAF inhibitors for the treatment of melanomas
Melanoma is an aggressive form of skin cancer. In the United
States alone, an estimated 75,000 new cases will be diagnosed in
2012.1 Although these numbers appear small when compared to
the incidence of NSCLC, melanoma represents a serious unmet
medical need since standard chemotherapies, such as dacarbazine,
are associated with response rates and 5-year survival rates lower
than 20%.57 In 2002, efforts from the Cancer Genome Project led to
the discovery of mutations in the BRAF gene.58 In melanomas, BRAF
mutations are found in approximately 50% of all cases. The most
prevalent BRAF gene mutation, accounting for more than 90% of
all BRAF mutations, occurs in exon 15 (T1799A) of the BRAF gene
and leads to the substitution of a valine residue by a glutamic acid
residue at position 600 in the corresponding protein (BRAFV600E).58
BRAF is a serine/threonine protein kinase and is a member of the
RAF family comprising ARAF, BRAF and CRAF. The RAF kinases
are located downstream of the RAS GTPases and upstream of
MEK and ERK in the MAPK signaling pathway (Fig. 9). Under nor-
mal conditions, RAS GTPases activate RAF proteins which mediate
their signals via homodimeric RAF (i.e., BRAF/BRAF) and heterodi-
meric RAF (i.e., BRAF/CRAF) complexes. In tumor cells, the mono-
meric BRAFV600E kinase constitutively activates the MAPK
pathway, leading to cell proliferation and survival.59,60
The recognition of BRAFV600E as an oncoprotein led to develop-
ment of selective inhibitors of BRAF.61,62 Representative examples
include vemurafenib (also known as PLX4032) and dabrafenib
(GSK-2118436) which are two structurally distinct, ATP-competi-
tive and selective BRAF inhibitors (Fig. 8A). In a phase III clinical
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Figure 8. (A) Representative chemical structures of BRAF inhibitors; (B) Combination therapies involving MEK and HSP90 inhibitors given in combination with BRAF














Figure 9. Overview of the MAPK signaling pathway.
S. Giroux / Bioorg. Med. Chem. Lett. 23 (2013) 394–401 399in patients with BRAFV600E-driven melanomas, a 960 mg twice-dai-
ly oral administration of vemurafenib led to markedly improved
overall survival at six months (84% vs 64% for the dacarbazine
treatment arm) and high response rates (48% vs 5% for the dacar-
bazine treatment arm).63 In August 2011, following these impres-
sive results, the FDA approved vemurafenib (Zelboraf™, Roche/
Genentech) for patients with advanced melanomas. It should be
noted that the early generation, unselective BRAF inhibitor sorafe-
nib failed to show beneﬁt in a phase III clinical trial with melanoma
patients.74 Notably, although selective BRAF inhibitors such as
vemurafenib and dabrafenib are generally well tolerated, approxi-
mately 30% of the patients experienced the formation of non-mel-
anoma skin lesions such as keratoacanthomas and squamous-cell
carcinomas.63 These lesions are believed to be the aftermath of
the paradoxical activation of the MAPK pathway by BRAF inhibi-
tor-induced formation of RAF dimers in wild-type BRAF cells with
RAS mutations.64
As for the EGFR- and ALK-targeted therapies, acquired resis-
tance to BRAF inhibition typically emerges within a year from
the start of the treatment.65 Interestingly, unlike the EGFR and
ALK cases where gatekeeper mutations represent major mecha-
nisms of acquired resistance, the gatekeeper mutation in BRAFV600E
has not been found in any relapsing patient tumors studied so far.
To date, several other mechanisms of acquired resistance to BRAF
inhibitors have already been discovered and they can be separated
into two general groups: MAPK-dependent and MAPK-indepen-
dent mechanisms. For example, MAPK-dependent resistance
mechanisms include upregulation of N-RAS,66 upregulation of
CRAF,67 activation of COT kinase (also known has MAP3K8),68
mutations in MEK,69 BRAFV600E ampliﬁcation70 and the emergence
of homodimeric truncated p61BRAFV600E proteins.71 All of these
mechanisms reactivate the MAPK pathway under sustained inhibi-
tion of the BRAFV600E kinase. MAPK-independent mechanisms in-
clude the loss of PTEN,72 upregulation of receptor tyrosine
kinases such as the platelet-derived growth factor receptor-b
(PDGFR-b)66 and insulin growth factor-1 receptor (IGF-1R).73 These
can mediate resistance via the activation of the PI3K/AKT pathway.Although MEK inhibitors have been generally inferior to BRAF
inhibitors in the context of melanomas,74 the dual inhibition of
MEK and BRAF appears to be a promising approach to address ac-
quired resistance to BRAF inhibition. At the present time, a phase
III clinical trial involving the combination of dabrafenib (GSK-
2118436) and the MEK inhibitor trametinib (GSK-1120212) is
underway (Fig. 8B). Additionally, two studies involving two BRAF
inhibitors (RAF-265 and LGX-818, Novartis) in combination with
a MEK inhibitor (MEK-162, Novartis) have recently begun. The
structures of LGX-818 and MEK-162 were not publicly disclosed
as of October 2012. Based on recent in vitro studies, it is likely that
clinical trials involving dual inhibition of BRAF and PI3K will be
conducted in the near future.75 Lastly, as for the cases of EGFR
and ALK, BRAFV600E is also a client protein of the molecular chaper-
one HSP90. The inhibition of HSP90 with XL-888, a structurally
400 S. Giroux / Bioorg. Med. Chem. Lett. 23 (2013) 394–401ovel HSP90 inhibitor, overcomes resistance in vemurafenib-resis-
tant melanoma cell lines.76 A combination of XL-888 and vemu-
rafenib is currently undergoing clinical investigation (Fig. 8B).
In summary, the recently discovered mechanisms of acquired
resistance to EGFR, ALK and BRAF inhibition have led to the design
of novel combination therapies using newer generations of small-
molecule inhibitors. As more resistance mechanisms will be dis-
covered, more high quality small-molecule inhibitors of varied
mechanisms will be required in order to achieve optimal clinical
beneﬁt.77 This highlights the need of a continued synergy between
clinicians, biologists, and medicinal chemists. Additionally, as can-
cer therapy seems to be moving towards an era of personalized
medicine,78,79 optimal screening for drug sensitivity markers will
be key to achieve greater beneﬁt to patients.
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